Stay updated on Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page

  1. Check
    4 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.0 to v3.7.1; the study record still displays a 403 error.
    Difference
    0.2%
    Check dated 2026-10-10T12:34:27.000Z thumbnail image
  2. Check
    11 days ago
    No Change Detected
  3. Check
    18 days ago
    No Change Detected
  4. Check
    25 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden error, replacing the usual content and leaving a simple Home link. This means the record is temporarily inaccessible and trial details are not viewable on this page.
    Difference
    19%
    Check dated 2026-09-19T18:36:47.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    NIH funding entries for 2017 and 2023 were added to the page. The revision history now shows v3.6.6, and the previous v3.6.5 entry was removed.
    Difference
    0.1%
    Check dated 2026-08-29T19:39:58.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The Plain Language Summary section was removed from the study record page, eliminating the patient-friendly overview of the trial and its purpose.
    Difference
    0.0%
    Check dated 2026-08-15T20:08:19.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    - The page revision has been updated to v3.6.5. The previous revision indicator v3.6.4 has been replaced.
    Difference
    0.0%
    Check dated 2026-08-08T18:29:51.000Z thumbnail image
  8. Check
    74 days ago
    Change Detected
    Summary
    The study record now includes new registry identifiers (UTN and EU CT) and adds data-sharing resources: a PDF with data-access procedures and an external data-sharing site, while older EngageZone links were removed. These changes place the trial's data-sharing framework and identifiers into current reference points for researchers and stakeholders.
    Difference
    0.1%
    Check dated 2026-08-01T15:24:50.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Resectable NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Resectable NSCLC Clinical Trial page.